Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli

A Study on Prevalence and Antimicrobial Resistance Pattern of Urinary Klebsiella pneumoniae in a Tertiary Care Centre in South India

“…Our strains showed moderate antibacterial resistance to the third generation cephalosporins, in contrary to the study conducted by Singh et al, (2003). ESBL producers are most often associated with UTIs (Melzer et al, 2007). The cost of hospitalization and duration of stay and mortality rate are higher with ESBL producing strains of Klebsiella spp.…”

Factores asociados a infecciones urinarias producidas por enterobacterias productoras de β-lactamasas de espectro extendido: una cohorte prospectiva

“…Por otro lado, las sepsis producidas por estos microorganismos presentan mayor mortalidad que las producidas por cepas no productoras de BLEE 9,10 , describiéndose el inicio tardío de un antimicrobiano adecuado como el principal factor de riesgo relacionado con la mortalidad 11 .…”

“…En sepsis donde se aíslan estos microorganismos, el foco que con mayor frecuencia se identifica es el urinario [10][11][12] generando infecciones que presentan una mayor dificultad en el tratamiento y una estadía hospitalaria más prolongada 14,15 que las infecciones del tracto urinario (ITU) producidas por patógenos no productores de BLEE. El tratamiento en estos casos se dificulta ya que estas bacterias presentan resistencia a la mayoría de los antimicrobianos que se utilizan de forma empírica en el tratamiento de las ITU, como son las cefalosporinas y quinolonas 16 .…”

Burden of Bloodstream Infection Caused by Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae Determined Using Multistate Modeling at a Swiss University Hospital and a Nationwide Predictive Model

“…1,2 ESBLs threaten the utility of commonly used empiric antibiotic therapy and have been associated with both delayed initiation of appropriate antibiotic therapy and excess mortality. [3][4][5][6] It is important to gain an accurate appreciation of the economic burden of ESBLproducing bacteria to justify the prioritization of infection control and antibiotic stewardship interventions required to confront this problem. 7 The excess length of stay (LOS) associated with an infection is the key driver of its cost from the hospital perspective.…”

“…[7][8][9] Estimation of this figure, however, is hampered by several methodological challenges. 4,10 An accurate estimation must account for the competing risks of death and increased LOS 5,11 and for time-dependent bias. 12 Failing to explicitly address the timing and onset of infection will always result in an overestimation of the attributable hospital LOS and therefore of cost.…”